CYTK Stock Overview
A late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
Cytokinetics, Incorporated Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$55.79 |
| 52 Week High | US$110.25 |
| 52 Week Low | US$25.98 |
| Beta | 0.75 |
| 11 Month Change | -0.34% |
| 3 Month Change | -3.63% |
| 1 Year Change | 70.35% |
| 33 Year Change | 73.53% |
| 5 Year Change | 320.74% |
| Change since IPO | -42.25% |
Recent News & Updates
Is Cytokinetics (NASDAQ:CYTK) Weighed On By Its Debt Load?
Aug 11
Cytokinetics' Aficamten: Heartfelt Potential Amid Market Woes
Jul 24Recent updates
Is Cytokinetics (NASDAQ:CYTK) Weighed On By Its Debt Load?
Aug 11Cytokinetics' Aficamten: Heartfelt Potential Amid Market Woes
Jul 24Cytokinetics Decides To Go It Alone
May 24Here's Why We Think Cytokinetics, Incorporated's (NASDAQ:CYTK) CEO Compensation Looks Fair for the time being
May 09Cytokinetics, Incorporated: Buyout Speculation Persists
Apr 01Cytokinetics: CEO Talks Down Buyout Prospects
Mar 16Cytokinetics Steps Up As Prime Target After Aficamten's HCM Triumph (Rating Upgrade)
Jan 12An Intrinsic Calculation For Cytokinetics, Incorporated (NASDAQ:CYTK) Suggests It's 37% Undervalued
Oct 05Analysts Are Betting On Cytokinetics, Incorporated (NASDAQ:CYTK) With A Big Upgrade This Week
May 07Shareholder Returns
| CYTK | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -2.4% | -1.0% | 0.2% |
| 1Y | 70.4% | 9.7% | 17.6% |
Return vs Industry: CYTK exceeded the US Biotechs industry which returned 9.3% over the past year.
Return vs Market: CYTK exceeded the US Market which returned 17.5% over the past year.
Price Volatility
| CYTK volatility | |
|---|---|
| CYTK Average Weekly Movement | 8.1% |
| Biotechs Industry Average Movement | 10.6% |
| Market Average Movement | 6.2% |
| 10% most volatile stocks in US Market | 14.8% |
| 10% least volatile stocks in US Market | 3.2% |
Stable Share Price: CYTK has not had significant price volatility in the past 3 months.
Volatility Over Time: CYTK's weekly volatility has decreased from 15% to 8% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1997 | 423 | Robert Blum | www.cytokinetics.com |
Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility. Its drug candidates include omecamtiv mecarbil, a novel cardiac myosin activator that is in Phase III clinical trial in patients with heart failure.
Cytokinetics, Incorporated Fundamentals Summary
| CYTK fundamental statistics | |
|---|---|
| Market cap | US$6.48b |
| Earnings (TTM) | -US$545.28m |
| Revenue (TTM) | US$3.13m |
2,069x
P/S Ratio-11.9x
P/E RatioIs CYTK overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| CYTK income statement (TTM) | |
|---|---|
| Revenue | US$3.13m |
| Cost of Revenue | US$328.68m |
| Gross Profit | -US$325.54m |
| Other Expenses | US$219.74m |
| Earnings | -US$545.28m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -4.69 |
| Gross Margin | -10,387.40% |
| Net Profit Margin | -17,398.82% |
| Debt/Equity Ratio | 603.4% |
How did CYTK perform over the long term?
See historical performance and comparison